These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30587963)

  • 1. Short-term treatment of irbesartan and hydrochlorothiazide decreases plasma N-terminal pro-brain natriuretic peptide levels in subjects with acute exacerbations of COPD.
    Jiang GY; Li Q; Lv YX
    Int J Chron Obstruct Pulmon Dis; 2019; 14():73-80. PubMed ID: 30587963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of nasal intermittent positive pressure ventilation on N-terminal pro-brain natriuretic peptide in patients with acute exacerbations of chronic obstructive pulmonary disease and type II respiratory failure].
    Wang Y; Yang Y; Chen P; Luo Y; Yang Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 37(4):325-31. PubMed ID: 22561561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of plasma N-terminal brain natriuretic pro-peptide in diagnosing elderly patients with acute exacerbation of COPD concurrent with left heart failure.
    Guo X; Nie H; Chen Q; Chen S; Deng N; Li R; Ding X; Hu S; Wang A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2931-2940. PubMed ID: 30275691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease.
    Chi SY; Kim EY; Ban HJ; Oh IJ; Kwon YS; Kim KS; Kim YI; Kim YC; Lim SC
    Lung; 2012 Jun; 190(3):271-6. PubMed ID: 22246552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease.
    Zhang J; Zhao G; Yu X; Pan X
    Respirology; 2012 May; 17(4):715-20. PubMed ID: 22394412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study.
    Tian F; Song W; Wang L; Zeng Q; Zhao Z; Feng N; Fan J; Wang Y; Wang J; Ma X
    Respir Res; 2021 Dec; 22(1):321. PubMed ID: 34961527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) as a Diagnostic Biomarker of Left Ventricular Systolic Dysfunction in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).
    Andrijevic I; Milutinov S; Lozanov Crvenkovic Z; Matijasevic J; Andrijevic A; Kovacevic T; Bokan D; Zaric B
    Lung; 2018 Oct; 196(5):583-590. PubMed ID: 29951921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotyping COPD exacerbations using imaging and blood-based biomarkers.
    Alotaibi NM; Chen V; Hollander Z; Hague CJ; Murphy DT; Leipsic JA; DeMarco ML; FitzGerald JM; McManus BM; Ng RT; Sin DD
    Int J Chron Obstruct Pulmon Dis; 2018; 13():217-229. PubMed ID: 29386890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Role of NT-proBNP for in-Hospital and 1-Year Mortality in Patients with Acute Exacerbations of COPD.
    Li H; Zeng Z; Cheng J; Hu G; Li Y; Wei L; Zhou Y; Ran P
    Int J Chron Obstruct Pulmon Dis; 2020; 15():57-67. PubMed ID: 32021144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.
    Labaki WW; Xia M; Murray S; Curtis JL; Barr RG; Bhatt SP; Bleecker ER; Hansel NN; Cooper CB; Dransfield MT; Wells JM; Hoffman EA; Kanner RE; Paine R; Ortega VE; Peters SP; Krishnan JA; Bowler RP; Couper DJ; Woodruff PG; Martinez FJ; Martinez CH; Han MK
    Respir Med; 2018 Jul; 140():87-93. PubMed ID: 29957287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction.
    Adrish M; Nannaka VB; Cano EJ; Bajantri B; Diaz-Fuentes G
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1183-1189. PubMed ID: 28458528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of right ventricular dysfunction on exercise capacity and quality of life and associations with serum NT-proBNP levels in COPD: an observational study.
    Ozdemirel TS; Ulaşli SS; Yetiş B; Karaçağlar E; Bayraktar N; Ulubay G
    Anadolu Kardiyol Derg; 2014 Jun; 14(4):370-7. PubMed ID: 24818627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study.
    Pervez MO; Winther JA; Brynildsen J; Strand H; Christensen G; Høiseth AD; Myhre PL; Røysland R; Lyngbakken MN; Omland T; Røsjø H
    Biomarkers; 2018 Nov; 23(7):654-663. PubMed ID: 29733687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation between N-terminal probrainnatriuretic peptide and prognosis of acute exacerbations of chronic obstructive pulmonary disease].
    Zhao CL; Zhang QR; Huang JW; Zhang L; Zhou M
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Feb; 41(2):95-99. PubMed ID: 29429214
    [No Abstract]   [Full Text] [Related]  

  • 15. NT-proBNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study.
    Høiseth AD; Omland T; Hagve TA; Brekke PH; Søyseth V
    Respir Res; 2012 Oct; 13(1):97. PubMed ID: 23107284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations.
    Chen YR; Chen V; Hollander Z; Leipsic JA; Hague CJ; DeMarco ML; FitzGerald JM; McManus BM; Ng RT; Sin DD
    PLoS One; 2017; 12(3):e0174063. PubMed ID: 28328968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease.
    Nishimura K; Nishimura T; Onishi K; Oga T; Hasegawa Y; Jones PW
    Int J Chron Obstruct Pulmon Dis; 2014; 9():155-62. PubMed ID: 24523584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminal proB-type natriuretic peptide levels aid the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease and renal dysfunction.
    Ouanes I; Jalloul F; Ayed S; Dachraoui F; Ouanes-Besbes L; Fekih Hassen M; Elatrous S; Abroug F
    Respirology; 2012 May; 17(4):660-6. PubMed ID: 22348741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.